inc.

Valeant Pharmaceuticals Intl Inc. (NYSE:VRX) announced that the FDA has …
insidetrade.co

It also provides Zovirax, an antiviral for recurrent herpes labialis and initial genital herpes; Syprine to treat patients with Wilson's disease; Elidel to treat atopic dermatitis; Prolensa for inflammation and pain following cataract surgery; Duromine …

4
Like
Save
Watch List: Neothetics, Inc. (NASDAQ:NEOT), Aviat Networks, Inc. (NASDAQ …
www.stocktranscript.com

On 22 June, Vical Incorporated (NASDAQ:VICL) announced top-line results from an ongoing randomized, double-blind, placebo controlled Phase 1/2 clinical study of its therapeutic genital herpes vaccine, designed to reduce viral shedding and genital …

2
Like
Save
Biotech Stocks that your portfolio will love – BioTime, Inc. (NYSEMKT:BTX …
www.wsobserver.com

The company, on June 22, 2015, reported top-line results from an ongoing randomized, double-blind, placebo controlled Phase 1/2 clinical study of its therapeutic genital herpes vaccine, designed to reduce viral shedding and genital herpes lesions in …

8
Like
Save
Stocks in Focus: Upland Software, Inc. (NASDAQ:UPLD), Vical Incorporated …
www.stocktranscript.com

On 22 June, Vical Incorporated (NASDAQ:VICL) announced top-line results from an ongoing randomized, double-blind, placebo controlled Phase 1/2 clinical study of its therapeutic genital herpes vaccine, designed to reduce viral shedding and genital …

9
Like
Save
Stock Activity: Westwood Holdings Group Inc. (NYSE:WHG), Halozyme …
www.propertymentorgroup.com

On 22 June, Vical Incorporated (NASDAQ:VICL) announced top-line results from an ongoing randomized, double-blind, placebo controlled Phase 1/2 clinical study of its therapeutic genital herpes vaccine, designed to reduce viral shedding and genital …

8
Like
Save
Morning Buzz: Genocea Biosciences, Inc. (NASDAQ:GNCA), Conatus …
www.stocktranscript.com

On 20 May, Genocea Biosciences, Inc. (NASDAQ:GNCA) announced positive top-line data from a Phase 2 dose optimization trial evaluating GEN-003 for the treatment of genital herpes. During the 28-day observation period immediately after completion of …

8
Like
Save
Today's Hot List: Genocea Biosciences, Inc. (NASDAQ:GNCA), Immunomedics …
www.stocktranscript.com

On 20 May, Genocea Biosciences, Inc. (NASDAQ:GNCA), announced positive top-line data from a Phase 2 dose optimization trial evaluating GEN-003 for the treatment of genital herpes. During the 28-day observation period immediately after completion of …

2
Like
Save
Don't Miss: Genocea Biosciences, Inc. (NASDAQ:GNCA), Annaly Capital …
www.stocktranscript.com

On 21 May, Genocea Biosciences, Inc. (NASDAQ:GNCA) announced positive top-line data from a Phase 2 dose optimization trial evaluating GEN-003 for the treatment of genital herpes. During the 28-day observation period immediately after completion of …

7
Like
Save